Ask AI
ProCE Banner Series

InterACT ADC Treatment Optimization & Care Team Activation in PROC: Enhancing Multidisciplinary Implementation, Toxicity Mitigation, and Workflow Readiness in Community Practice

Join this interprofessional, case-based workshop for practical guidance on implementing antibody–drug conjugate (ADC) care in platinum-resistant ovarian cancer, including recurrence biomarker testing, ADC candidate selection, treatment sequencing, infusion readiness, patient/caregiver education, and protocol-driven toxicity management. Using evidence from SORAYA and MIRASOL for FRα-directed therapy, DESTINY-PanTumor02 for HER2-expressing tumors, and emerging RAINFOL-02, BEHOLD-1, REJOICE-Ovarian01, and NaPi2b-directed programs, community care teams will work through FRα-high disease with baseline ocular and neuropathy risks, HER2-positive recurrent disease with pending FRα results, and urgent ocular, pulmonary, neurologic, and hematologic toxicities through progressive InterACT cases, a live patient perspective, and an ADC AE Readiness Lab.

  AAPA
  | ACPE
  | AMA
  | ANCC
Who Should Attend

This activity is intended for multidisciplinary teams caring for patients with ovarian cancer, including oncologists, oncology nurses, APPs, physician associates, pharmacists, infusion staff, care coordinators, patient navigators, and other HCPs responsible for treatment selection, ADC delivery, toxicity monitoring, care transitions, and patient/caregiver education.

Topics

Gynecologic Cancers

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
This activity is designed to improve learners’ knowledge, confidence, competence, and performance in evidence-aligned ADC implementation for PROC by strengthening recurrence biomarker workflows, ADC candidacy and sequencing decisions, toxicity mitigation, dosing decisions, infusion readiness, patient/caregiver education, and team-based care coordination in community oncology settings.

Target Audience
This activity is intended for multidisciplinary teams caring for patients with ovarian cancer, including oncologists, oncology nurses, APPs, physician associates, pharmacists, infusion staff, care coordinators, patient navigators, and other HCPs responsible for treatment selection, ADC delivery, toxicity monitoring, care transitions, and patient/caregiver education.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Apply current guideline recommendations, recurrence biomarker testing results, prior treatment history, disease tempo, comorbidities, baseline toxicity risk, and patient goals to identify appropriate candidates for ADC therapy, non-ADC systemic therapy, clinical trial referral, or supportive-care integration in PROC

  • Differentiate currently available and emerging ADC strategies in recurrent ovarian cancer by target, payload, evidence base, biomarker requirement, anticipated toxicity profile, dosing considerations, and role in treatment sequencing

  • Select evidence-aligned baseline assessments, prophylactic measures, monitoring intervals, dose-modification steps, and escalation pathways for ADC-associated ocular toxicity, neuropathy, interstitial lung involvement/ILD-pneumonitis, cytopenias, gastrointestinal toxicity, fatigue, and infusion-related events

  • Implement a multidisciplinary ADC Care Pathway that assigns team roles for biomarker ordering and tracking, treatment readiness, patient/caregiver education, symptom triage, specialty referral, dose decision-making, documentation, and follow-up across community practice

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

Clinical Care Options, LLC dba Decera Clinical Education designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: Specific to each event 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification

Title: A blue and black sign with white textDescription automatically generated

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.0 MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through Decera Clinical Education’s Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Decera Clinical Education permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

ILNA Recertification Points 

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas: 

  • Care Continuum (OCN, CBCN, CPHON, AOCNP, ROCN) - 0.5*

  • Oncology Nursing Practice (OCN) - 0.5*

  • Professional Practice/Performance (TCTCN, AOCNP, ROCN) - 0.25*

  • Roles of the APRN (AOCNP) - 0.25*

  • Symptom Management, Palliative Care, Supportive Care (OCN, CPHON, AOCNP) - 1.0*

  • Treatment (AOCNP, CBCN, CPHON, OCN, ROCN) - 1.0*

Total Points: 1.0* 

*Note that the course content applies to multiple subject areas across multiple credentials. The numerical value indicated above is the maximum number of points that can be claimed in each subject area.  The total amount of ILNA points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential you are renewing. 

IPCE Credit Designation

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/657115052be04.jpg

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

CME Passport

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Clinical Care Options, LLC dba Decera Clinical Education

Supporters

This activity is supported by an independent educational grant from Genmab.

Genmab

For customer support please click here.

Mailing Address:

 

Decera Clinical Education
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191